Results 181 to 190 of about 47,090 (208)
Some of the next articles are maybe not open access.
European Journal of Immunology, 1997
AbstractLeIF, a gene homologue of the eukaryotic initiation factor 4A was first described as a leishmanial antigen that induced a Th1‐type T cell response in peripheral blood mononuclear cells (PBMC) from leishmaniasis patients. Moreover, the interferon (IFN)‐γ production by PBMC was found to be interleukin (IL)‐12 dependent.
P, Probst +5 more
openaire +2 more sources
AbstractLeIF, a gene homologue of the eukaryotic initiation factor 4A was first described as a leishmanial antigen that induced a Th1‐type T cell response in peripheral blood mononuclear cells (PBMC) from leishmaniasis patients. Moreover, the interferon (IFN)‐γ production by PBMC was found to be interleukin (IL)‐12 dependent.
P, Probst +5 more
openaire +2 more sources
Journal of Hepatology, 1999
It has been reported that expression of costimulatory molecules, such as B7, on tumors is essential for priming tumor-specific cytotoxic T-lymphocytes (CTLs). Here, we have attempted to induce murine hepatoma-specific CTLs by immunizing with the B7-1-gene-expressing hepatoma cells, and to identify the epitope(s) presented on the hepatoma cells.The B7-1-
K, Nakatsuka +3 more
openaire +2 more sources
It has been reported that expression of costimulatory molecules, such as B7, on tumors is essential for priming tumor-specific cytotoxic T-lymphocytes (CTLs). Here, we have attempted to induce murine hepatoma-specific CTLs by immunizing with the B7-1-gene-expressing hepatoma cells, and to identify the epitope(s) presented on the hepatoma cells.The B7-1-
K, Nakatsuka +3 more
openaire +2 more sources
The Journal of Immunology, 1998
Abstract The differentiation of CD4+ T cells into a Th1 vs Th2 phenotype profoundly influences the outcome of autoimmune and infectious diseases. B7 costimulation has been shown to affect the production of both Th1 and Th2 cytokines, depending on the system studied.
A N, Schweitzer, A H, Sharpe
openaire +2 more sources
Abstract The differentiation of CD4+ T cells into a Th1 vs Th2 phenotype profoundly influences the outcome of autoimmune and infectious diseases. B7 costimulation has been shown to affect the production of both Th1 and Th2 cytokines, depending on the system studied.
A N, Schweitzer, A H, Sharpe
openaire +2 more sources
Cancer Immunology, Immunotherapy, 2000
We have previously shown that B7-2 (CD86) and, to a lesser extent, B7-1 (CD80) contribute to the curative effectiveness of low-dose melphalan (L-phenylalanine mustard) for mice bearing a large MOPC-315 tumor under conditions that lead to the acquisition of potent cytotoxic T lymphocyte (CTL) activity at the tumor site. Since B7-1 and B7-2 are expressed
D K, Sojka, R N, La Motte, M B, Mokyr
openaire +2 more sources
We have previously shown that B7-2 (CD86) and, to a lesser extent, B7-1 (CD80) contribute to the curative effectiveness of low-dose melphalan (L-phenylalanine mustard) for mice bearing a large MOPC-315 tumor under conditions that lead to the acquisition of potent cytotoxic T lymphocyte (CTL) activity at the tumor site. Since B7-1 and B7-2 are expressed
D K, Sojka, R N, La Motte, M B, Mokyr
openaire +2 more sources
Cancer gene therapy, 1996
The aim of this study was to determine if human melanoma cells could be molecularly modified by particle-mediated gene transfer with a "gene gun", using genes for interferon-gamma (IFN-gamma), the B7-1 costimulatory molecule (CD80), and human leukocyte antigen (HLA)-A2, to augment expression of both HLA molecules and B7-1. Established and early passage
M R, Albertini +5 more
openaire +1 more source
The aim of this study was to determine if human melanoma cells could be molecularly modified by particle-mediated gene transfer with a "gene gun", using genes for interferon-gamma (IFN-gamma), the B7-1 costimulatory molecule (CD80), and human leukocyte antigen (HLA)-A2, to augment expression of both HLA molecules and B7-1. Established and early passage
M R, Albertini +5 more
openaire +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
A guide to antigen processing and presentation
Nature Reviews Immunology, 2022Hidde Ploegh +2 more
exaly
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Cell, 2023Leyuan Ma
exaly
MR1 antigen presentation to MAIT cells and other MR1-restricted T cells
Nature Reviews Immunology, 2023JOSÉ Villadangos +2 more
exaly